- Home
- TOYO vs LCTX Comparison
TOYO vs LCTX Comparison
Compare TOYO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- LCTX
- Stock Information
- Founded
- TOYO 2022
- LCTX 1990
- Country
- TOYO Japan
- LCTX United States
- Employees
- TOYO N/A
- LCTX N/A
- Industry
- TOYO
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOYO
- LCTX Health Care
- Exchange
- TOYO NYSE
- LCTX Nasdaq
- Market Cap
- TOYO 115.2M
- LCTX 110.2M
- IPO Year
- TOYO N/A
- LCTX N/A
- Fundamental
- Price
- TOYO $3.62
- LCTX $0.55
- Analyst Decision
- TOYO
- LCTX Strong Buy
- Analyst Count
- TOYO 0
- LCTX 4
- Target Price
- TOYO N/A
- LCTX $5.25
- AVG Volume (30 Days)
- TOYO 2.6M
- LCTX 4.2M
- Earning Date
- TOYO 08-21-2024
- LCTX 11-14-2024
- Dividend Yield
- TOYO N/A
- LCTX N/A
- EPS Growth
- TOYO N/A
- LCTX N/A
- EPS
- TOYO 0.76
- LCTX N/A
- Revenue
- TOYO $200,455,385.00
- LCTX $8,719,000.00
- Revenue This Year
- TOYO N/A
- LCTX N/A
- Revenue Next Year
- TOYO N/A
- LCTX $123.52
- P/E Ratio
- TOYO $4.58
- LCTX N/A
- Revenue Growth
- TOYO N/A
- LCTX N/A
- 52 Week Low
- TOYO $1.36
- LCTX $0.48
- 52 Week High
- TOYO $15.61
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- LCTX 38.21
- Support Level
- TOYO N/A
- LCTX $0.48
- Resistance Level
- TOYO N/A
- LCTX $0.61
- Average True Range (ATR)
- TOYO 0.00
- LCTX 0.05
- MACD
- TOYO 0.00
- LCTX 0.00
- Stochastic Oscillator
- TOYO 0.00
- LCTX 38.93
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.